No Data
Huachuang Securities: The commercial retail and social services sectors are experiencing a recovery in customer flow, with a double impact of fundamental improvement and valuation repair.
Looking ahead to 2025, service consumption is set to experience a rapid reversal and recovery, with a "magnificent" fundamental landscape and a double boost from valuation recovery, establishing a trend.
Express News | Jiangsu Wuzhong Pharmaceutical Development: The company's product Lianqin Zhenzhu Dripping Pills has been converted from prescription medicine to over-the-counter medicine.
Minsheng Securities: In Q3 24, the commercial retail industry was affected by pressure on the demand side, with slowdown in revenue and profit growth in multiple sectors.
In Q1-3 2024, the total retail sales of 35.36 trillion yuan, yoy +3.35%, single Q3 total retail sales of 11.76 trillion yuan, yoy +2.69%, the growth rate sequentially slowed down.
Jiangsu Wuzhong Pharmaceutical Development (600200) 2024 Third Quarter Report Review: Aisufei continues high growth, promising prospects for medical beauty business.
Investment highlights: The company disclosed its performance in the third quarter of 2024: Revenue for 2024 Q1-3 was 1.65 billion yuan (+9.6%, representing year-on-year growth rate, the same below), net profit attributable to equity holders was 0.045 billion yuan (+311.54%), net profit after deducting non-recurring gains and losses
Announcement of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. on the main operating data from January to September 2024
Jiangsu Wu Zhong Medicine Development Co., Ltd. Report for the third quarter of 2024
No Data
No Data